<DOC>
	<DOCNO>NCT01089413</DOCNO>
	<brief_summary>This observational study ass treatment duration , progression-free survival , reason stop treatment patient tumor characteristic bevacizumab [ Avastin ] treatment patient metastatic colorectal cancer . Data collect approximately 34 month . The target sample size &gt; 300 patient .</brief_summary>
	<brief_title>Observational Study Bevacizumab Avastin Patients With Metastatic Colorectal Cancer ( AVASTART )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patient =/ &lt; 18 year age metastatic colorectal cancer patient physician prescribed bevacizumab [ Avastin ] treatment 1st line metastatic colorectal cancer patient , give write informed consent hypersensitivity recombinant human humanise antibody pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>